Applied Dna Scie Financials
This page shows Applied Dna Scie (APDN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Applied Dna Scie has an operating margin of -750.9%, meaning the company retains $-751 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -646.7% the prior year.
Applied Dna Scie's revenue grew a modest 1.1% year-over-year to $2.1M. This slow but positive growth earns a score of 32/100.
Applied Dna Scie carries a low D/E ratio of 1.08, meaning only $1.08 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 71/100, indicating a strong balance sheet with room for future borrowing.
Applied Dna Scie's current ratio of 0.91 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 16/100, which could limit financial flexibility.
While Applied Dna Scie generated -$12.2M in operating cash flow, capex of $313K consumed most of it, leaving -$12.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Applied Dna Scie passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Applied Dna Scie generates $0.81 in operating cash flow (-$12.2M OCF vs -$15.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Applied Dna Scie earns $-83.2 in operating income for every $1 of interest expense (-$16.0M vs $193K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Applied Dna Scie generated $2.1M in revenue in fiscal year 2025. This represents an increase of 1.1% from the prior year.
Applied Dna Scie's EBITDA was -$15.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.3% from the prior year.
Applied Dna Scie generated -$12.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 11.1% from the prior year.
Applied Dna Scie reported -$15.2M in net income in fiscal year 2025. This represents a decrease of 116.8% from the prior year.
Applied Dna Scie earned $-134.23 per diluted share (EPS) in fiscal year 2025. This represents an increase of 90.2% from the prior year.
Applied Dna Scie held $1.7M in cash against $0 in long-term debt as of fiscal year 2025.
Applied Dna Scie had 2M shares outstanding in fiscal year 2025. This represents an increase of 11987.2% from the prior year.
Applied Dna Scie's gross margin was 39.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 6.9 percentage points from the prior year.
Applied Dna Scie's operating margin was -750.9% in fiscal year 2025, reflecting core business profitability. This is down 104.2 percentage points from the prior year.
Applied Dna Scie's net profit margin was -709.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 378.6 percentage points from the prior year.
Applied Dna Scie invested $6.0M in research and development in fiscal year 2025. This represents an increase of 67.4% from the prior year.
Applied Dna Scie invested $313K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 23.2% from the prior year.
APDN Income Statement
| Metric | Q1'26 | Q3'25 | Q2'25 | Q3'24 | Q1'25 | Q3'23 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $565K+85.7% | $304K-69.0% | $983K-66.3% | $2.9M+227.4% | $891K-79.3% | $4.3M-2.5% | $4.4M-16.2% | $5.3M |
| Cost of Revenue | $250K-16.4% | $299K-51.1% | $613K-62.8% | $1.6M+149.7% | $660K-79.7% | $3.3M+25.3% | $2.6M-9.9% | $2.9M |
| Gross Profit | $315K+6047.3% | $5K-98.6% | $371K-70.8% | $1.3M+449.3% | $231K-77.8% | $1.0M-42.5% | $1.8M-24.0% | $2.4M |
| R&D Expenses | $459K-40.3% | $769K-9.5% | $849K+1.6% | $836K-10.7% | $936K+8.4% | $863K-12.7% | $989K+1.8% | $971K |
| SG&A Expenses | $13.3M+355.5% | $2.9M-1.8% | $3.0M-9.4% | $3.3M+6.7% | $3.1M+1.7% | $3.0M-13.9% | $3.5M+34.2% | $2.6M |
| Operating Income | -$18.7M-406.4% | -$3.7M-6.7% | -$3.5M-21.1% | -$2.9M+24.5% | -$3.8M-32.6% | -$2.9M-5.6% | -$2.7M-121.8% | -$1.2M |
| Interest Expense | $9K-77.3% | $40K-33.3% | $60K+125.3% | $27K-19.6% | $33K | $0-100.0% | $4K-1.3% | $4K |
| Income Tax | N/A | N/A | N/A | $0 | N/A | $0 | $0 | $0 |
| Net Income | -$18.6M-371.3% | -$3.9M-19.4% | -$3.3M-6.6% | -$3.1M-180.5% | -$1.1M+1.7% | -$1.1M-291.1% | $588K+115.3% | -$3.8M |
| EPS (Diluted) | $-2.08 | $-34.00-121.5% | $-15.35 | $-4.80-177.5% | $-1.73-1230.8% | $-0.13 | $0.91+403.3% | $-0.30 |
APDN Balance Sheet
| Metric | Q1'26 | Q3'25 | Q2'25 | Q3'24 | Q1'25 | Q3'23 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $20.7M+108.3% | $9.9M-23.8% | $13.0M+1.9% | $12.8M+29.0% | $9.9M-27.4% | $13.7M-28.8% | $19.2M-5.5% | $20.3M |
| Current Assets | $5.1M-9.2% | $5.6M-33.2% | $8.4M+4.8% | $8.0M+75.3% | $4.6M-43.5% | $8.1M-47.2% | $15.4M-16.1% | $18.3M |
| Cash & Equivalents | $2.5M-48.2% | $4.7M-30.7% | $6.8M+16.6% | $5.9M+74.2% | $3.4M-53.0% | $7.2M-41.8% | $12.3M-4.6% | $12.9M |
| Inventory | $90K-73.4% | $339K-2.9% | $349K-19.4% | $433K+14.7% | $377K+14.3% | $330K-9.8% | $366K-23.3% | $477K |
| Accounts Receivable | $547K+174.7% | $199K-71.1% | $690K+110.2% | $328K-27.2% | $451K+76.4% | $256K-87.0% | $2.0M-51.5% | $4.1M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.2M-24.1% | $2.9M+4.8% | $2.8M-26.4% | $3.8M-33.9% | $5.8M-34.1% | $8.8M-4.6% | $9.2M-17.3% | $11.1M |
| Current Liabilities | $2.2M+8.3% | $2.0M+7.5% | $1.9M-21.0% | $2.4M-7.3% | $2.6M-9.0% | $2.8M-22.2% | $3.7M+9.8% | $3.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $18.8M+159.4% | $7.3M-30.6% | $10.5M+14.4% | $9.1M+116.0% | $4.2M-14.5% | $5.0M-50.5% | $10.0M+9.2% | $9.2M |
| Retained Earnings | -$397.8M-6.4% | -$373.9M-5.5% | -$354.4M-14.5% | -$309.7M-2.0% | -$303.6M-0.4% | -$302.4M-2.3% | -$295.8M+0.2% | -$296.3M |
APDN Cash Flow Statement
| Metric | Q1'26 | Q3'25 | Q2'25 | Q3'24 | Q1'25 | Q3'23 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.5M-110.8% | -$2.6M+17.4% | -$3.2M+6.0% | -$3.4M+9.8% | -$3.8M-40.2% | -$2.7M-1350.0% | $214K+109.0% | -$2.4M |
| Capital Expenditures | $0-100.0% | $11K-94.1% | $185K-50.1% | $371K | N/A | -$87-100.2% | $54K | $0 |
| Free Cash Flow | -$3.1M-17.4% | -$2.6M+21.6% | -$3.4M+10.3% | -$3.8M | N/A | -$2.7M-1774.4% | $160K+106.7% | -$2.4M |
| Investing Cash Flow | -$3.0M-13615.3% | -$22K+88.2% | -$185K+50.1% | -$371K | N/A | -$925K-1601.7% | -$54K-220.8% | $45K |
| Financing Cash Flow | $9.3M+1188.3% | $723K-19.6% | $899K+330.2% | -$391K-1013.9% | -$35K-46868.0% | $75 | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
APDN Financial Ratios
| Metric | Q1'26 | Q3'25 | Q2'25 | Q3'24 | Q1'25 | Q3'23 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.8%+54.1pp | 1.7%-36.0pp | 37.7%-5.8pp | 43.5%+17.6pp | 25.9%+1.7pp | 24.2%-16.8pp | 41.0%-4.2pp | 45.2% |
| Operating Margin | -3308.9%-2095.3pp | -1213.6%-861.5pp | -352.0%-254.0pp | -98.0%+327.2pp | -425.2%-358.7pp | -66.5%-5.1pp | -61.4%-38.2pp | -23.2% |
| Net Margin | -3288.6%-1992.5pp | -1296.1%-960.1pp | -336.0%-229.8pp | -106.3%+17.8pp | -124.0%-97.8pp | -26.2%-39.5pp | 13.4%+86.4pp | -73.0% |
| Return on Equity | N/A | 15.2% | N/A | N/A | N/A | N/A | 5.9% | N/A |
| Return on Assets | -89.8%-50.1pp | -39.7%-14.4pp | -25.4%-5.7pp | -19.6%-8.5pp | -11.2%-1.7pp | -9.4%-12.5pp | 3.1%+22.0pp | -18.9% |
| Current Ratio | 2.32-0.4 | 2.76-1.7 | 4.45+1.1 | 3.36+1.6 | 1.77-1.1 | 2.86-1.4 | 4.21-1.3 | 5.51 |
| Debt-to-Equity | 0.12-0.3 | 0.41+0.1 | 0.27-0.1 | 0.42-0.9 | 1.37-0.4 | 1.77+0.9 | 0.92-0.3 | 1.22 |
| FCF Margin | -395.6%+472.2pp | -867.8%-525.1pp | -342.7%-295.0pp | -47.8% | N/A | -42.6%-46.3pp | 3.6%+48.9pp | -45.3% |
Note: The current ratio is below 1.0 (0.91), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Applied Dna Scie's annual revenue?
Applied Dna Scie (APDN) reported $2.1M in total revenue for fiscal year 2025. This represents a 1.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Applied Dna Scie's revenue growing?
Applied Dna Scie (APDN) revenue grew by 1.1% year-over-year, from $2.1M to $2.1M in fiscal year 2025.
Is Applied Dna Scie profitable?
No, Applied Dna Scie (APDN) reported a net income of -$15.2M in fiscal year 2025, with a net profit margin of -709.5%.
What is Applied Dna Scie's earnings per share (EPS)?
Applied Dna Scie (APDN) reported diluted earnings per share of $-134.23 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Applied Dna Scie's EBITDA?
Applied Dna Scie (APDN) had EBITDA of -$15.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Applied Dna Scie's gross margin?
Applied Dna Scie (APDN) had a gross margin of 39.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Applied Dna Scie's operating margin?
Applied Dna Scie (APDN) had an operating margin of -750.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Applied Dna Scie's net profit margin?
Applied Dna Scie (APDN) had a net profit margin of -709.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Applied Dna Scie's free cash flow?
Applied Dna Scie (APDN) generated -$12.6M in free cash flow during fiscal year 2025. This represents a 11.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Applied Dna Scie's operating cash flow?
Applied Dna Scie (APDN) generated -$12.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Applied Dna Scie's total assets?
Applied Dna Scie (APDN) had $4.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Applied Dna Scie's capital expenditures?
Applied Dna Scie (APDN) invested $313K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Applied Dna Scie spend on research and development?
Applied Dna Scie (APDN) invested $6.0M in research and development during fiscal year 2025.
How many shares does Applied Dna Scie have outstanding?
Applied Dna Scie (APDN) had 2M shares outstanding as of fiscal year 2025.
What is Applied Dna Scie's current ratio?
Applied Dna Scie (APDN) had a current ratio of 0.91 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Applied Dna Scie's debt-to-equity ratio?
Applied Dna Scie (APDN) had a debt-to-equity ratio of 1.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Applied Dna Scie's return on assets (ROA)?
Applied Dna Scie (APDN) had a return on assets of -341.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Applied Dna Scie's cash runway?
Based on fiscal year 2025 data, Applied Dna Scie (APDN) had $1.7M in cash against an annual operating cash burn of $12.2M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Applied Dna Scie's Piotroski F-Score?
Applied Dna Scie (APDN) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Applied Dna Scie's earnings high quality?
Applied Dna Scie (APDN) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Applied Dna Scie cover its interest payments?
Applied Dna Scie (APDN) has an interest coverage ratio of -83.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Applied Dna Scie?
Applied Dna Scie (APDN) scores 24 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.